CN Patent

CN114480382A — 用于抑制SURF4基因表达的RNAi试剂和组合物

Assigned to Peking University · Expires 2022-05-13 · 4y expired

What this patent protects

本发明为用于抑制SURF4基因表达的RNAi试剂和组合物，涉及能够抑制SURF4表达的短反义寡核苷酸和RNAi试剂。本发明还涉及包含一种或多种所述短反义寡核苷酸或RNAi试剂的组合物。本发明还涉及所述短反义寡核苷酸、RNAi试剂或组合物在受试者中降低血脂，或治疗或预防与血脂异常相关的疾病中的用途。

USPTO Abstract

本发明为用于抑制SURF4基因表达的RNAi试剂和组合物，涉及能够抑制SURF4表达的短反义寡核苷酸和RNAi试剂。本发明还涉及包含一种或多种所述短反义寡核苷酸或RNAi试剂的组合物。本发明还涉及所述短反义寡核苷酸、RNAi试剂或组合物在受试者中降低血脂，或治疗或预防与血脂异常相关的疾病中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN114480382A
Jurisdiction
CN
Classification
—
Expires
2022-05-13
Drug substance claim
No
Drug product claim
No
Assignee
Peking University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.